{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T22:24:46Z","timestamp":1704320686872},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,9,7]],"date-time":"2010-09-07T00:00:00Z","timestamp":1283817600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s11908-010-0133-0","type":"journal-article","created":{"date-parts":[[2010,9,6]],"date-time":"2010-09-06T00:39:50Z","timestamp":1283733590000},"page":"471-478","source":"Crossref","is-referenced-by-count":6,"title":["The Role of Second-Generation Antifungal Triazoles for Treatment of the Endemic Mycoses"],"prefix":"10.1007","volume":"12","author":[{"given":"Alison G.","family":"Freifeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Ryan","family":"Bariola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Andes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,7]]},"reference":[{"key":"133_CR1","unstructured":"Centers for Disease Control and Prevention, National Center for Zoonotic, Vector-Borne, and Enteric Diseases: A\u2013Z index for foodborne, bacterial, and mycotic diseases. Available at http:\/\/www.cdc.gov\/nczved\/divisions\/dfbmd\/diseases\/index.html . Accessed July 2010."},{"key":"133_CR2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/521259","volume":"45","author":"LJ Wheat","year":"2007","unstructured":"Wheat LJ, Freifeld AG, Kleiman MB, et al.: Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45:807\u2013825.","journal-title":"Clin Infect Dis"},{"key":"133_CR3","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1086\/588300","volume":"46","author":"SW Chapman","year":"2008","unstructured":"Chapman SW, Dismukes WE, Proia LA, et al.: Clinical practice guidelines for the management of blastomycosis: 2008 update by the infectious Diseases Society of America. Clin Infect Dis 2008, 46:1801\u20131812.","journal-title":"Clin Infect Dis"},{"key":"133_CR4","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1086\/496991","volume":"41","author":"JN Galgiani","year":"2005","unstructured":"Galgiani JN, Ampel NM, Blair JE, et al.: Coccidioidomycosis. Clin Infect Dis 2005, 41:1217\u20131223.","journal-title":"Clin Infect Dis"},{"key":"133_CR5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0002-9343(97)00151-4","volume":"103","author":"J Wheat","year":"1997","unstructured":"Wheat J, MaWhinney S, Hafner R, et al.: Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am J Med 1997, 103:223\u2013232.","journal-title":"Am J Med"},{"key":"133_CR6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1086\/514539","volume":"25","author":"PG Pappas","year":"1997","unstructured":"Pappas PG, Bradsher RW, Kauffman CA, et al.: Treatment of blastomycosis with higher doses of fluconazole. The National Institute Of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1997, 25:200\u2013205.","journal-title":"Clin Infect Dis"},{"key":"133_CR7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1086\/605499","volume":"49","author":"JM Lestner","year":"2009","unstructured":"\u2022 Lestner JM, Roberts SA, Moore CB, et al.: Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009, 49:928\u2013930. This article describes an important study that identifies the upper limit for the itraconazole therapeutic index.","journal-title":"Clin Infect Dis"},{"key":"133_CR8","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/AAC.44.6.1734-1736.2000","volume":"44","author":"RK Li","year":"2000","unstructured":"Li RK, Ciblak MA, Nordoff N, et al.: In vitro activities of voriconazole, itraconazole, and amphotericin B against blastomyces dermatitidis, coccidioides immitis, and histoplasma capsulatum. Antimicrob Agents Chemother 2000, 44:1734\u20131736.","journal-title":"Antimicrob Agents Chemother"},{"key":"133_CR9","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.00163-06","volume":"50","author":"F Sabatelli","year":"2006","unstructured":"Sabatelli F, Patel R, Mann PA, et al.: In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006, 50:2009\u20132015.","journal-title":"Antimicrob Agents Chemother"},{"key":"133_CR10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/13693780500088416","volume":"43","author":"GM Gonzalez","year":"2005","unstructured":"Gonzalez GM, Fothergill AW, Sutton DA, et al.: In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol 2005, 43:281\u2013284.","journal-title":"Med Mycol"},{"key":"133_CR11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00199879","volume":"46","author":"T Zimmermann","year":"1994","unstructured":"Zimmermann T, Yeates RA, Laufen H, et al.: Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994, 46:147\u2013150.","journal-title":"Eur J Clin Pharmacol"},{"key":"133_CR12","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1086\/504492","volume":"43","author":"E Dodds Ashley","year":"2006","unstructured":"Dodds Ashley E, Lewis R, Lewis J, et al.: Pharmacology of systemic antifungal agents. Clin Infect Dis 2006, 43:S28\u2013S39.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"133_CR13","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/jac\/dki220","volume":"56","author":"AG Prentice","year":"2005","unstructured":"Prentice AG, Glasmacher A: Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005, 56(Suppl 1):i17\u2013i22.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"133_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1365-2125.2003.01994.x","volume":"56","author":"L Purkins","year":"2003","unstructured":"Purkins L, Wood N, Kleinermans D, et al.: Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003, 56(Suppl 1):17\u201323.","journal-title":"Br J Clin Pharmacol"},{"key":"133_CR15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","volume":"53","author":"G Krishna","year":"2009","unstructured":"\u2022 Krishna G, Moton A, Ma L, et al.: Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009, 53:958\u2013966. The results of this investigation demonstrate the importance of the acidic gastric environment for optimal absorption of posaconazole.","journal-title":"Antimicrob Agents Chemother"},{"key":"133_CR16","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1128\/AAC.01178-08","volume":"53","author":"ES Dodds Ashley","year":"2009","unstructured":"\u2022 Dodds Ashley ES, Varkey JB, Krishna G, et al.: Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. Antimicrob Agents Chemother 2009, 53:2960\u20132964. The authors describe an important investigation of pharmacokinetics for patients unable to take posaconazole by mouth.","journal-title":"Antimicrob Agents Chemother"},{"key":"133_CR17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM199401273300407","volume":"330","author":"JA Como","year":"1994","unstructured":"Como JA, Dismukes WE: Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994, 330:263\u2013272.","journal-title":"N Engl J Med"},{"key":"133_CR18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00007691-199710000-00007","volume":"19","author":"JM Poirier","year":"1997","unstructured":"Poirier JM, Hardy S, Isnard F, et al.: Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen. Ther Drug Monit 1997, 19:525\u2013529.","journal-title":"Ther Drug Monit"},{"key":"133_CR19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00762-06","volume":"51","author":"MA Thiel","year":"2007","unstructured":"Thiel MA, Zinkernagel AS, Burhenne J, et al.: Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother 2007, 51:239\u2013244.","journal-title":"Antimicrob Agents Chemother"},{"key":"133_CR20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1086\/377131","volume":"37","author":"I Lutsar","year":"2003","unstructured":"Lutsar I, Roffey S, Troke P: Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003, 37:728\u2013732.","journal-title":"Clin Infect Dis"},{"key":"133_CR21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","volume":"26","author":"L Willems","year":"2001","unstructured":"Willems L, van der Geest R, de Beule K: Itraconazole oral solution and intravenous formulations:a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001, 26:159\u2013169.","journal-title":"J Clin Pharm Ther"},{"key":"133_CR22","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1128\/AAC.40.8.1910","volume":"40","author":"JR Perfect","year":"1996","unstructured":"Perfect JR, Cox GM, Dodge RK, Schell WA: In vitro and in vivo efficacies of the azole SCH56592 against cryptococcus neoformans. Antimicrob Agents Chemother 1996, 40:1910\u20131913.","journal-title":"Antimicrob Agents Chemother"},{"key":"133_CR23","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/jac\/dki288","volume":"56","author":"P Pitisuttithum","year":"2005","unstructured":"Pitisuttithum P, Negroni R, Graybill JR, et al.: Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005, 56:745\u2013755.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"133_CR24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1439-0507.2005.01113.x","volume":"48","author":"E Muhl","year":"2005","unstructured":"Muhl E: Antimycotic drugs under continuous renal replacement therapy. Mycoses 2005, 48(Suppl 1):56\u201360.","journal-title":"Mycoses"},{"key":"133_CR25","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","volume":"41","author":"Z Desta","year":"2002","unstructured":"Desta Z, Zhao X, Shin JG, Flockhart DA: Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002, 41:913\u2013958.","journal-title":"Clin Pharmacokinet"},{"key":"133_CR26","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","volume":"45","author":"U Theuretzbacher","year":"2006","unstructured":"Theuretzbacher U, Ihle F, Derendorf H: Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006, 45:649\u2013663.","journal-title":"Clin Pharmacokinet"},{"key":"133_CR27","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1086\/424662","volume":"39","author":"AE Boyd","year":"2004","unstructured":"Boyd AE, Modi S, Howard SJ, et al.: Adverse reactions to voriconazole. Clin Infect Dis 2004, 39:1241\u20131244.","journal-title":"Clin Infect Dis"},{"key":"133_CR28","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","volume":"50","author":"J Smith","year":"2006","unstructured":"Smith J, Safdar N, Knasinski V, et al.: Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006, 50:1570\u20131572.","journal-title":"Antimicrob Agents Chemother"},{"key":"133_CR29","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","volume":"48","author":"RJ Bruggemann","year":"2009","unstructured":"\u2022 Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al.: Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009, 48:1441\u20131458. This article is a thorough and clinically useful review of triazole drug interactions.","journal-title":"Clin Infect Dis"},{"key":"133_CR30","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1177\/106002809402801009","volume":"28","author":"MO Gearhart","year":"1994","unstructured":"Gearhart MO: Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother 1994, 28:1177\u20131181.","journal-title":"Ann Pharmacother"},{"key":"133_CR31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","volume":"46","author":"A Pascual","year":"2008","unstructured":"\u2022 Pascual A, Calandra T, Bolay S, et al.: Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008, 46:201\u2013211. This article describes an important clinical study that demonstrates a role for voriconazole therapeutic drug monitoring to optimize efficacy and reduce toxicity.","journal-title":"Clin Infect Dis"},{"key":"133_CR32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10096-005-1281-2","volume":"24","author":"SB Girois","year":"2005","unstructured":"Girois SB, Chapuis F, Decullier E, Revol BG: Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 2005, 24:119\u2013130.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"133_CR33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1517\/13543784.11.3.409","volume":"11","author":"HL Hoffman","year":"2002","unstructured":"Hoffman HL, Rathbun RC: Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 2002, 11:409\u2013429.","journal-title":"Expert Opin Investig Drugs"},{"key":"133_CR34","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/clinids\/22.2.336","volume":"22","author":"TJ Pursley","year":"1996","unstructured":"Pursley TJ, Blomquist IK, Abraham J, et al.: Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996, 22:336\u2013340.","journal-title":"Clin Infect Dis"},{"key":"133_CR35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000239592","volume":"43","author":"DA Stevens","year":"1997","unstructured":"Stevens DA, Diaz M, Negroni R, et al.: Safety evaluation of chronic fluconazole therapy. fluconazole pan-American study group. Chemotherapy 1997, 43:371\u2013377.","journal-title":"Chemotherapy"},{"key":"133_CR36","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/S0140-6736(00)04891-1","volume":"357","author":"SR Ahmad","year":"2001","unstructured":"Ahmad SR, Singer SJ, Leissa BG: Congestive heart failure associated with itraconazole. Lancet 2001, 357:1766\u20131767.","journal-title":"Lancet"},{"key":"133_CR37","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1128\/AAC.01148-07","volume":"53","author":"A Freifeld","year":"2009","unstructured":"\u2022 Freifeld A, Proia L, Andes D, et al.: Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009, 53:1648\u20131651. The authors present a case series suggesting the utility of voriconazole for therapy of endemic fungal infections.","journal-title":"Antimicrob Agents Chemother"},{"key":"133_CR38","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/604712","volume":"49","author":"J Cuellar-Rodriguez","year":"2009","unstructured":"\u2022 Cuellar-Rodriguez J, Avery RK, Lard M, et al.: Histoplasmosis in solid organ transplant recipients: 10\u00a0years of experience at a large transplant center in an endemic area. Clin Infect Dis 2009, 49:710\u2013716. The authors describe a case series highlighting the rarity of histoplasmosis in solid organ transplant recipients, and the generally excellent outcomes with prompt appropriate antifungal therapy.","journal-title":"Clin Infect Dis"},{"key":"133_CR39","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/jac\/dkl133","volume":"57","author":"LJ Wheat","year":"2006","unstructured":"Wheat LJ, Connolly P, Smedema M, et al.: Activity of newer triazoles against histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother 2006, 57:1235\u20131239.","journal-title":"J Antimicrob Chemother"},{"key":"133_CR40","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1128\/AAC.44.10.2604-2608.2000","volume":"44","author":"P Connolly","year":"2000","unstructured":"Connolly P, Wheat LJ, Schnizlein-Bick C, et al.: Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob Agents Chemother 2000, 44:2604\u20132608.","journal-title":"Antimicrob Agents Chemother"},{"key":"133_CR41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jinf.2006.05.006","volume":"54","author":"A Restrepo","year":"2007","unstructured":"Restrepo A, Tobon A, Clark B, et al.: Salvage treatment of histoplasmosis with posaconazole. J Infect 2007, 54:319\u2013327.","journal-title":"J Infect"},{"key":"133_CR42","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jinf.2005.01.001","volume":"51","author":"B Clark","year":"2005","unstructured":"Clark B, Foster R, Tunbridge A, Green S: A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole. J Infect 2005, 51:e177\u2013e180.","journal-title":"J Infect"},{"key":"133_CR43","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.inf.0000207475.89745.51","volume":"25","author":"J Panicker","year":"2006","unstructured":"Panicker J, Walsh T, Kamani N: Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole. Pediatr Infect Dis J 2006, 25:377\u2013379.","journal-title":"Pediatr Infect Dis J"},{"key":"133_CR44","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/13693780600803870","volume":"44","author":"SM Borgia","year":"2006","unstructured":"Borgia SM, Fuller JD, Sarabia A, El-Helou P: Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen. Med Mycol 2006, 44:659\u2013664.","journal-title":"Med Mycol"},{"key":"133_CR45","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1086\/429319","volume":"40","author":"M Bakleh","year":"2005","unstructured":"Bakleh M, Aksamit AJ, Tleyjeh IM, Marshall WF: Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis 2005, 40:e69\u2013e71.","journal-title":"Clin Infect Dis"},{"key":"133_CR46","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/650579","volume":"50","author":"JR Bariola","year":"2010","unstructured":"\u2022 Bariola JR, Perry P, Pappas PG, et al.: Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis 2010, 50:797\u2013804. The authors present a case series of CNS blastomycosis suggesting that lipid amphotericin B followed by a prolonged course of oral azole, preferably voriconazole, is effective in most cases.","journal-title":"Clin Infect Dis"},{"key":"133_CR47","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1399-3062.2007.00227.x","volume":"9","author":"GM Gauthier","year":"2007","unstructured":"Gauthier GM, Safdar N, Klein BS, Andes DR: Blastomycosis in solid organ transplant recipients. Transpl Infect Dis 2007, 9:310\u2013317.","journal-title":"Transpl Infect Dis"},{"key":"133_CR48","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1086\/430303","volume":"40","author":"GM Anstead","year":"2005","unstructured":"Anstead GM, Corcoran G, Lewis J, et al.: Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005, 40:1770\u20131776.","journal-title":"Clin Infect Dis"},{"key":"133_CR49","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.07-0114","volume":"132","author":"DA Stevens","year":"2007","unstructured":"Stevens DA, Rendon A, Gaona-Flores V, et al.: Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007, 132:952\u2013958.","journal-title":"Chest"},{"key":"133_CR50","first-page":"46","volume":"7","author":"U Wollina","year":"2009","unstructured":"Wollina U, Hansel G, Vennewald I, et al.: Successful treatment of relapsing disseminated coccidioidomycosis with cutaneous involvement with posaconazole. J Dtsch Dermatol Ges 2009, 7:46\u201349.","journal-title":"J Dtsch Dermatol Ges"},{"key":"133_CR51","first-page":"940","volume":"98","author":"SJ Antony","year":"2006","unstructured":"Antony SJ, Jurczyk P, Brumble L: Successful use of combination antifungal therapy in the treatment of coccidioides meningitis. J Natl Med Assoc 2006, 98:940\u2013942.","journal-title":"J Natl Med Assoc"},{"key":"133_CR52","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1128\/AAC.48.6.2341.2004","volume":"48","author":"LA Proia","year":"2004","unstructured":"Proia LA, Tenorio AR: Successful use of voriconazole for treatment of coccidioides meningitis. Antimicrob Agents Chemother 2004, 48:2341.","journal-title":"Antimicrob Agents Chemother"},{"key":"133_CR53","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","volume":"53","author":"D Andes","year":"2009","unstructured":"\u2022 Andes D, Pascual A, Marchetti O: Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009, 53:24\u201334. This article is a useful review of indications for and how to incorporate antifungal therapeutic drug monitoring into clinical practice.","journal-title":"Antimicrob Agents Chemother"},{"key":"133_CR54","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/FTD.0b013e318167d0e0","volume":"30","author":"J Smith","year":"2008","unstructured":"\u2022 Smith J, Andes D: Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008, 30:167\u2013172. This article is a review of the data available to discern the utility of antifungal therapeutic drug monitoring.","journal-title":"Ther Drug Monit"},{"issue":"3 Pt 2","key":"133_CR55","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/0190-9622(90)70261-F","volume":"23","author":"RM Tucker","year":"1990","unstructured":"Tucker RM, Denning DW, Arathoon EG, et al.: Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol 1990, 23(3 Pt 2):593\u2013601.","journal-title":"J Am Acad Dermatol"},{"key":"133_CR56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","volume":"44","author":"TJ Walsh","year":"2007","unstructured":"Walsh TJ, Raad I, Patterson TF, et al.: Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007, 44:2\u201312.","journal-title":"Clin Infect Dis"},{"key":"133_CR57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaad.2009.09.033","volume":"62","author":"EW Cowen","year":"2010","unstructured":"\u2022 Cowen EW, Nguyen JC, Miller DD, et al.: Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010, 62:31\u201337. This report highlights the evolving link between chronic photosensitivity during prolonged voriconazole treatment and squamous cell carcinoma of the skin.","journal-title":"J Am Acad Dermatol"},{"key":"133_CR58","first-page":"300","volume":"146","author":"DD Miller","year":"2010","unstructured":"\u2022 Miller DD, Cowen EW, Nguyen JC, et al.: Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010, 146:300\u2013304. There may also be a link between chronic photosensitivity during prolonged voriconazole treatment and melanoma.","journal-title":"Arch Dermatol"},{"key":"133_CR59","doi-asserted-by":"crossref","unstructured":"\u2022 Vadnerkar A, Nguyen MH, Mitsani D, et al.: Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010. Another case report of chronic voriconazole treatment being linked to photosensitivity-related squamous cell carcinoma of the skin.","DOI":"10.1016\/j.healun.2010.05.022"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-010-0133-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11908-010-0133-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-010-0133-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T17:49:02Z","timestamp":1559584142000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11908-010-0133-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,7]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1007\/s11908-010-0133-0","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"value":"1523-3847","type":"print"},{"value":"1534-3146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,7]]}}}